Skip to main content

27-06-2022 | ASCO 2022 | Conference coverage | Video

Highlights from ASCO 22 Annual Meeting: an expert discussion with Andrea Apolo & Elizabeth Plimack

share
SHARE

Speakers: Andrea Apolo and Elizabeth Plimack

Andrea Apolo and Elizabeth Plimack discuss highlights of the ASCO 22 Annual Meeting. Here, they talk about some of the exciting new data presented on the use of antibody-drug conjugates targeting HER2, which are starting to show promise for the treatment of urothelial carcinoma (UC). They also review the use of tyrosine kinase inhibitors as agents in the metastatic setting, as outlined in two studies ATLANTIS and COSMIC-021. Finally, they comment on results indicating that DNA repair alterations can predict response to chemotherapy, as well as the general need for biomarkers to guide patient selection and treatment decisions.

This activity is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany.